WO2001096355A1 - Derives de nucleosides - Google Patents
Derives de nucleosides Download PDFInfo
- Publication number
- WO2001096355A1 WO2001096355A1 PCT/JP2001/005011 JP0105011W WO0196355A1 WO 2001096355 A1 WO2001096355 A1 WO 2001096355A1 JP 0105011 W JP0105011 W JP 0105011W WO 0196355 A1 WO0196355 A1 WO 0196355A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- acid
- derivative
- nucleoside derivative
- nucleoside
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
Definitions
- the present invention relates to novel nucleoside derivatives.
- Nucleic acids are highly functional macromolecules responsible for the accumulation and transmission of genetic information in living bodies. Specific recognition between nucleic acids or between nucleic acids and proteins plays an important role in the expression and regulation of nucleic acid functions. With the rapid development of genetic engineering and molecular biology in recent years, the mechanism of function expression has been further understood at the molecular level. Many causative genes of the disease have been elucidated, and the mechanism of its onset has been elucidated. against this backdrop, gene therapy, which treats diseases at the gene level by using specific recognition molecules that mimic the mode of recognition of natural nucleic acids as drugs, has attracted attention.
- a gene transfer method that artificially introduces a defective or defective gene sequence into a patient's gene involves the synthesis of a protein that causes disease by binding an antisense molecule to mRNA in a base-specific manner.
- the “antisense method”, which inhibits the DNA, and the “antigene method”, which combines the antisense moiety with the DNA region encoding the pathogenic protein to inhibit the transcription step, have been studied.
- the so-called antisense molecules used in the “antisense method” and “antigene method” have many properties, among which 1) high nucleobase sequence recognition ability, ⁇ ⁇ high stability of the complex, ) High stability to biological substances, especially enzymes, 4) high cell toxicity, 5) specific interaction with nucleic acids, and 6) non-toxicity to living organisms are important.
- antisense molecules include 1) derivatives modified around phosphate bonds, 2) derivatives modified at the glycosyl bond or hydroxyl group of the ribose sugar moiety, 3) derivatives modified at the base moiety, 4) There are nucleic acid model molecules having a skeleton structure other than the sugar-phosphate skeleton.
- derivatives of 1) include phosphorothioate type in which the oxygen atom of the phosphate group of the phosphodiester bond is substituted with a sulfur atom, phosphorodithioate type, phosphoroamidate type, and methyl
- Derivatives of 2) include phosphonate-type and methylphosphonothioate-type oligonucleotides; ⁇ -anomeric oligonucleotides in which a base is coordinated with a sugar moiety in a manner opposite to a 3-darcosyl bond; Oligonucleotide in which the 3'-5 'phosphodiester bond has been changed to a 2'-5' bond using a liponucleotide.
- 2'-methoxy compound in which the 2'-position of the report is methylated is a derivative of 3
- Modifying bases such as 5-fluorouracil (5-FU), in which the 5-position of peracyl is substituted with fluorine, and fluorescent etenoadenosine; and sugars are used as derivatives of 4).
- Peptide nucleic acids ( ⁇ ⁇ ) having a peptide skeleton in place of the acid skeleton OE. Uhlman, A. Peyman, Chem. Rev., 1990, 90, 544; OE. Uhlman, A. Peyman, G. Breipol, D .. Will, Angew, Chem. Int., Ed. Engl., 199 8, 37, 2796, etc.).
- peptide nucleic acid not only has base-specific recognition ability and can withstand enzymatic degradation, but also has a very high affinity with nucleic acid because it has a neutral peptide chain in the main chain. It is a compound that has attracted attention because it has the advantages of having two tees and being able to easily obtain an arbitrary sequence by an amide bond formation reaction.
- too high an affinity, such as binding to a target containing a mismatch is a disadvantage, and because of having a hydrophobic peptide chain, oligomers of 15-mers or more cannot be used in cells. Disadvantages have been reported, such as nonspecific adsorption to inner proteins and poor water solubility.
- An object of the present invention is to provide a novel nucleoside derivative. More specifically, the present invention is useful as an antisense molecule because it has a higher affinity for a nucleic acid base sequence than a natural nucleic acid and has a property of being less susceptible to hydrolysis by in vivo enzymes. And a novel nucleoside derivative.
- the nucleoside derivative provided by the present invention is a compound useful as an antisense molecule in an antisense method.
- the present invention has been completed based on such findings.
- the present invention relates to nucleoside derivatives and methods for producing the same, as described in the following 1. to 14.
- a nucleoside derivative represented by the general formula (1) 1. A nucleoside derivative represented by the general formula (1).
- X is the same or different and is a pyrimidine or purine nucleobase or a derivative thereof
- ⁇ and Y ′ are the same or different and are serine, threonine, oretin, aspartic acid, glutamic acid, lysine, arginine, cysteine , Methionine, ⁇ -hydroxylysine, N-aminoethyldaricin, N-aminoethylserine, N-aminoethyllysine, N-aminoethylorutin, N-aminoethylaspara.formic acid, N-aminoethylglutamic acid, homo glutamate, beta one Chiokarupo two Ruasuparagin acid is any of at least one amino acid or amino acid derivative selected arch Sairyoku Lupo sulfonyl glutamic acid, and (from 5 Chio Cal Poni Le group homo consisting glutamic acid, R 1 represents a
- X represented by the general formula (1) is substituted with peracyl represented by the formula (2) or a derivative thereof.
- 1 ⁇ and 1 ⁇ are the same or different and are an oxygen atom or a sulfur atom, and R 4 is a hydrogen atom, a halogen, an alkyl group, an alkenyl group or an alkynyl group.
- X represented by the general formula (1) is: 5-fluorouracil, 5-promouracil, 5-odouracil, 2-thioperacil, 4-thioperacil, 2,4-dithioperacil, 5-methylperacil, 5-vinylperacil, 5 - Echiniruurashiru, 5 one Furuoroshitoshin, 5-bromo, 5- ® one Doshitoshin, 5- Echirushi cytosine, hypoxanthine, 8-Furuoroguanin, 8 Puromoguanin, 8 - 3 one Doguanin, iota, New 6 - Etenoadenin, 8 _ Furuoroadenin 9.
- m is an integer of 1 to 3
- R 5 is an oxygen atom or a sulfur atom
- * means a binding site to A in the nucleoside derivative represented by the general formula (1). Where A is a single pound.
- m is an integer of :! to 3
- R 6 is an oxygen atom or a sulfur atom
- * means a binding site to A in the nucleoside derivative represented by the general formula (1). , Where A is a single pound.
- 'R 7 is a hydrogen atom, a carboxymethyl group, a carboxyethyl group, a hydroxymethyl group, an aminobutyl group, or an aminopropyl group, and * is the same as A in the nucleoside derivative represented by the general formula (1).
- A is a carbonyl group or a thiocarbonyl group.
- Step 1 aminating the 5'-hydroxyl group of a nucleoside or a derivative thereof to produce a 5'-amino-nucleoside derivative, the following formula
- R 5 is an oxygen atom or a sulfur atom
- m is an integer of 1 to 3
- n is an integer of 1 to 100.
- a derivative thereof with pentachlorophenyl trichloroacetate Reacting to produce an amino acid- ⁇ -pentachlorophenyl ester derivative, and the 5′-amino-nucleoside derivative obtained in Steps 1 and 2 and the amino acid- ⁇ -pentanol phenyl, respectively.
- the method for producing a nucleoside derivative according to claim 4 comprising a step 3 of reacting with an ester derivative.
- step 1 l
- step 2 for deprotecting the C-terminus of the monomer
- step 3 for deprotecting the N-terminus of the monomer
- step 2 The oligomer or polymer of the nucleoside derivative according to 5, further comprising a step 4 of subjecting the C-terminal deprotected product to a condensation reaction with the N-terminal deprotected product obtained in the step 3, and a step of repeating the steps 2 to 4 as necessary.
- N 2 to 100
- R 7 is a hydrogen atom, a carboxymethyl group, a carboxyethyl group, a hydroxymethyl group, an aminobutyl group or an aminopropyl group, D represents a carboxyl protecting group, and E represents an amino protecting group.
- step 1 is carried out in the presence of N, N'-carbonilimidazole, phosgene, N, N'-thiocarbonilimidazole or thiophosgene.
- X is the same or different and is pyrimidine or purine nucleobase or And Y and Y 'are the same or different, and serine, threonine, ordinine, aspartic acid, glutamic acid, lysine, arginine, cysteine, methionine, ⁇ -hydroxylysine, ⁇ -aminoethyldaricin, ⁇ -Aminoethylserine, ⁇ -aminoethylilericin, ⁇ -aminoethylo ⁇ !
- Renitin ⁇ -aminoethylaspartic acid, ⁇ -aminoethylglutamic acid, homoglutamic acid, ⁇ -thiocarbinylaspartic acid, arch talent Luponyldararylemin At least one selected from the group consisting of an acid, and ⁇ -thiocarbonyl homoglutamic acid
- R 1 is a hydrogen atom or a hydroxyl group, and ⁇ is any of a single bond, a carbonyl group or a thiocarbonyl group.
- F is a 9-fluorenylcarbonyl group, and G is a hydroxyl group or a benzylester group. 1 is an integer from 0 to 5.
- X is the same or different and is a pyrimidine or purine nucleobase or a derivative thereof
- Y and Y ′ are the same or different and are serine, threonine, or Ditin, aspartic acid, glutamic acid, lysine, arginine, cysteine, methionine, ⁇ -hydroxylysine, ⁇ -aminoethyldaricin, ⁇ -aminoethylserine, ⁇ -aminoethylilericin, ⁇ -aminoethylornithin, ⁇ At least one selected from the group consisting of —aminoethylaspartic acid, ⁇ -aminoethylglutamic acid, homoglutamic acid, ⁇ -thiocarbonylaspartic acid, arch talented luponylglutamic acid, and ⁇ - ⁇ thiocarponylhomogglutamic acid
- R 1 is a hydrogen atom or
- FIG. 1 is a schematic diagram showing the steps of solid-phase synthesis of the nucleoside derivative (PRNA oligomer or polymer) of the present invention.
- FIG. 2 is a chromatogram showing the results of HPLC analysis of PRNA oligomer 1 produced (solid phase synthesis) in Example 10.
- the nucleoside derivative of the present invention is a novel compound which has not been described in the literature, and is represented by the following formula (1).
- X is the same or different and is a pyrimidine or purine nucleobase or a derivative thereof
- ⁇ and Y ′ are the same or different and are serine, threonine, ordinine, aspartic acid, glutamic acid, lysine, arginine, cysteine , Thionine, d-hydroxylysine, N-aminoethyl ⁇ / glycine, N-aminoethylserine, N-aminoethyllysine, N-aminoethylorutin, N-aminoethylaspartic acid, N-aminoethylglutamic acid, homo Glutamic acid, ⁇ -thiocarbonylaspartic acid, archocarbonylglutamic acid, and ⁇ -thiocarbonylhomoglutamic acid, at least one selected from the group consisting of amino acids or amino acid derivatives, and R 1 is a hydrogen atom or a hydroxy
- Each group of the nucleoside derivative represented by the above general formula (1) is specifically as follows.
- the pyrimidine nucleobase represented by X means peracyl, cytosine and thymine, and the purine nucleobase means adenine and guanine.
- the derivative of these nucleobases is not particularly limited, but examples thereof include halogenated derivatives of peracyl, cytosine, thymine, adenine or guanine, deamino derivatives, and derivatives having a sulfur atom in place of an oxygen atom. it can.
- R 2 and R 3 are the same or different and are an oxygen atom or a sulfur atom
- R 4 is a hydrogen atom, a halogen, an alkyl group, an alkenyl group or an alkynyl group.
- Specific examples include a fluorine atom, a bromine atom, an iodine atom and a chlorine atom, and a fluorine atom, a bromine atom and an iodine atom are preferred.
- alkyl group examples include a methyl group, an ethyl group, a propyl group, an isopropyl group, a butyl group, an isobutyl group, a t-butyl group, a pentyl group and a hexyl group.
- a straight-chain or branched lower alkyl group having from 6 to 6 can be mentioned.
- Alkenyl groups include vinyl, aryl, propyl, isopropyl, 2-methyl-1-propenyl, 2-methylaryl, 3-butenyl, 4-pentenyl, and 5- Examples thereof include a linear or branched lower alkenyl group having 1 to 6 carbon atoms, such as a xenyl group and a 1,3-butanenyl group.
- alkynyl group examples include ethynyl group, 2-propynyl group, 2-butynyl group, 2-pentynyl group, 2-hexynyl group, and 2-penten-4-ynyl, etc.
- alkynyl group examples include ethynyl group, 2-propynyl group, 2-butynyl group, 2-pentynyl group, 2-hexynyl group, and 2-penten-4-ynyl, etc.
- alkynyl group examples include ethynyl group, 2-propynyl group, 2-butynyl group, 2-pentynyl group, 2-hexynyl group, and 2-penten-4-ynyl, etc.
- alkynyl group examples include ethynyl group, 2-propynyl group, 2-butynyl group, 2-pentynyl group, 2-hexynyl group, and 2-penten-4
- cytosine derivatives include halogenated cytosine derivatives such as 5-fluorocytosine, 5-promocytosine and 5-hydroxycytosine; and cytosine derivatives having an alkynyl group such as 5-ethynylcytosine. Preferably 5-fluorocytosine.
- guanine derivative examples include a deaminoguanine derivative such as hypoxanthine, and a halogenated guanine derivative such as 8-fluoroguanine, 8-promoguanine, and 8-odoguanine. Preferred are hypoxanthin and 8-promoguanine.
- halogenated adenine derivatives such as 8-fluoroadenine, 8-bromoadenine and 8-odoadenine.
- 8-fluoroadenine 8-bromoadenine
- 8-odoadenine 8-odoadenine.
- the nucleoside derivative (1) of the present invention may have the above-mentioned one kind of base as the nucleic acid base (X) in one molecule, or may have two or more kinds of different bases. Good. Suitable nucleobases include peracyl, thymine, cytosine, guanine and adenine.
- the amino acid represented by Y or Y 'or a derivative thereof is not particularly limited as long as it does not exhibit immunogenicity due to its polymerization (oligoamino acid, polyamino acid).
- Amino acids such as serine, threonine, aspartic acid, dalminic acid, lysine, arginine, cystine, methionine and ordinine; and hydroxylysine, ⁇ -aminoethyldaricin, ⁇ ⁇ -aminoethylserine, ⁇ -aminoethyllysine , ⁇ -aminoethylorutin, ⁇ -aminoethylaspartic acid, ⁇ -aminoethylglutamic acid, homoglutamic acid, ⁇ -thiocarbonylamino acid (3-thiocarponylaspartic acid, arch talent Luponylglutamic acid, ⁇ - Derivatives of amino acids such as serine,
- glutamic acid aspartic acid, homodalminic acid, ⁇ -thiocarborylaspartic acid, r-thiocarbonyldalminic acid, ⁇ -thiocarbonylhomoglutamic acid and ⁇ -aminoethyldaricin.
- these amino acids and amino acid derivatives may be any of d form, 1 form, and racemic form.
- the monomer of the amino acid represented by (Y- ( ⁇ ′ ⁇ ) ⁇ — or a derivative thereof or the ⁇ terminus of the polymer thereof may be a free amino group, but is not particularly limited. It may have any functional group having a bond, a carbamic acid bond, a thiocarbamic acid bond, a urea bond, a thiourea bond or a phosphoramide bond, and the C-terminal may also be a free carboxy group. It is preferable, but not particularly limited, and may have any functional group having, for example, an amide bond or an ester bond.
- Amino acids and amino acid derivatives represented by ⁇ are bonded to the 5'-carbon of the sugar-base moiety by an amide bond, thioamide bond, carbamic acid bond, thiocarbamic acid bond, dithiocarbamic acid bond, urea bond, thiourea bond, ester bond, etc. But said 5 The position of the functional group in the amino acid or amino acid derivative which binds to the '-carbon via these bonds is not particularly limited.
- aspartic acid a dicarboxylic acid
- glutamic acid has an ⁇ - or ⁇ -carboxyl group
- homoglutamic acid has an ⁇ - or ⁇ -carboxyl group
- 5,- An amide bond can be formed with an amino group
- / 3-thiocarbonylaspartic acid is an ⁇ -thiocarpoxyl group
- r-thiocarbonyldarminic acid is an r-thiocarboxyl group
- 'A thioamide bond can be formed with the -amino group.
- 1 is usually an integer of 0 to 5, preferably 0 to 2, and more preferably 0 or 1.
- ⁇ is usually an integer of 1 to 100, preferably an integer of 6 to 50, and more preferably an integer of 8 to 20.
- the nucleoside derivative targeted by the present invention includes a 5′-amino group of 5′-amino-nucleoside directly or via a carbonyl, thiocarbonyl, carbamic acid, thiocarbamic acid, urea or thiourea bond.
- the nucleoside derivative of the present invention specifically includes compounds I, ⁇ , and ⁇ shown below.
- m is an integer of 1 to 3
- R 5 is an oxygen atom or a sulfur atom
- * means a binding site to A in the nucleoside derivative represented by the general formula (1). ].
- m is an integer of 1 to 3
- R 6 is an oxygen atom or a sulfur atom
- * means a binding site to A in the nucleoside derivative represented by the general formula (1). ].
- X, Y ′, R ⁇ 1 and n are the same as above.
- A is a carbonyl group or a thiocarbonyl group.
- Y is the following formula (iii)
- R 7 is a hydrogen atom, a carboxymethyl group, a carboxyethyl group, a hydroxymethyl group, an aminobutyl group, an aminopropyl group or a 4-amino-3-hydroxypropyl group, and * is represented by the general formula (1).
- R 7 is a hydrogen atom, a carboxymethyl group, a carboxyethyl group, a hydroxymethyl group, an aminobutyl group, an aminopropyl group or a 4-amino-3-hydroxypropyl group, and * is represented by the general formula (1).
- PR nucleoside derivative
- NA1 ⁇ -type
- PRNA2 ⁇ -type
- PRNA3 AEG-type
- the nucleoside derivative of the present invention can be produced by various methods.
- the 5′-amino-nucleoside is obtained by aminating the hydroxyl group (5′-hydroxyl group) bonded to the 5 ′ carbon of the sugar moiety of the nucleoside of general formula (la) or a derivative thereof.
- Step 2 reacting the nucleoside derivative (lb) and the amino acid derivative (Id) respectively produced by the above-mentioned steps to obtain the nucleic acid of the present invention.
- It can be produced Sid derivative (1-i) (Step 3).
- step 3 various methods for substituting a hydroxyl group with an amino group can be used. Specifically, for example, the Mitsunobu method (T. Hata, et al., J. Chem. So, Perkin 1, 306, (1976) ), T. Hata, et al., Chem. Lett., (1975) pp.977-980) can be applied. Specifically, it can be carried out according to the following formula.
- Step (1) is a reaction for azidating the 5′-7] acid group of the nucleoside or its derivative (la).
- the nucleoside or its derivative (ia) can be converted to triphenylphosphine (PRh 3 ), lithium azide (L iN 3) and carbon tetrabromide (CB r 4) 5 by reacting with '-N 3 - nucleoside derivatives (la') can be obtained.
- the reaction solvent is a hydrocarbon-based solvent such as cyclohexane, benzene, and toluene; dichloromethane, chloroform, dichloroethane, trichloroethane, Halogenated hydrocarbon solvents such as benzene and the like; water; alcohol solvents such as methanol, ethanol and isopropanol; carboxylic acids such as formic acid and acetic acid; ether solvents such as tetrahydrofuran and dioxane; acetic anhydride; acetone; Dimethylphosphoramide / dimethylamide; dimethylsulfoxide; acetonitrile; THF; Preferred are dimethylformamide and dimethylsulfoxide, which are preferably used after drying.
- the amount of the solvent to be used is generally 20 to 1000 parts by weight, preferably about 50 to 100 parts by weight, per 1 part by weight of the nucleoside of the general formula (la) or a derivative thereof.
- the triphenyl phosphine, lithium azide and tetracarbon are used in an amount of about 1 to 10 mol, respectively, per 1 mol of the nucleoside of the general formula (la) or a derivative thereof.
- Such a reaction can be carried out usually within a range of 0 to 80%, and is completed in about: 36 hours.
- the reaction is stopped by adding a polar solvent such as methanol, and then the solvent is distilled off. Note that by performing the ordinary purification method such as further chromatography as necessary, 5 '- ⁇ 3 - nucleoside derivative (la) leaves in isolation.
- Step (2) is a reaction for aminating the azido group of the 5′-N 3 -nucleoside derivative (la ′), and can be performed, for example, by reacting with hydrogen in a suitable solvent.
- This reaction is preferably performed in the presence of a catalyst such as palladium-supported carbon or ruthenium-supported carbon.
- the reaction solvent is a hydrocarbon-based solvent such as cyclohexane, benzene, and toluene; a hydrocarbon-based solvent such as dichloromethane, chloroform, dichloroethane, trichloroethane, and cyclobenzene; water; methanol, ethanol Alcohol solvents such as isopropanol; carboxylic acids such as formic acid and acetic acid; ether solvents such as tetrahydrofuran and dioxane; acetic anhydride; acetone; polar solvents such as dimethylformamide and dimethylsulfoxide.
- alcohol solvents such as methanol and ethanol, and dimethylformamide.
- Such a reaction can be carried out usually at room temperature, preferably in the range of 0 to 5, and is completed in about 0.5 to 48 hours.
- the residue obtained by concentrating the reaction filtrate is reprecipitated with a methanol-based solvent or the like, whereby a 5′-NH 2 -nucleoside derivative of the general formula (lb) can be obtained.
- the methanol-based solvent it is preferable to use a mixed solvent of methanol and ethanol.
- Step 2 can be performed by reacting the amino acid (lc) with pentachlorophenyltrichloroacetate in a suitable solvent.
- the reaction solvent is a hydrocarbon-based solvent such as cyclohexane, benzene, and toluene; a hydrocarbon-based solvent such as dichloromethane, chloroform, dichloroethane, trichloroethane, and cyclobenzene; water; methanol, ethanol Alcohol solvents such as isopropanol; carboxylic acids such as formic acid and acetic acid; ether solvents such as tetrahydrofuran and dioxane; acetic anhydride; acetone; dimethylformamide; acetonitrile; Preferred are polar solvents such as dimethylformamide and dimethylsulfoxide.
- the amount of the solvent to be used is generally 10 to 1000 parts by weight, preferably about 20 to 100 parts by weight, per 1 part by weight of the amino acid.
- the reaction can be performed in a range of 0 to 80, and is completed in about 0.5 to 48 hours.
- Step 3 can be carried out by adding the 5′-book 2 -nucleoside derivative (lb) obtained in Step 1 to the reaction solution of Step 2 above and mixing the resulting mixture. )) Of the present invention (P RNA 1).
- P RNA 1 Used in reaction 5 '-NH 2 - ratio of nucleoside derivatives (lb) with an amino acid derivative (Id) is not particularly limited, 5' _NH 2 - nucleoside derivative (lb) polyamic Bruno acid derivative per 1 mol (Id) The range is about 0.8 to 1 mol.
- the reaction is carried out at a temperature in the range of 0 to 40, preferably 0 to 40 ° C, and is generally completed in about 24 to 48 hours.
- the reaction product obtained by each of the above reactions is separated from the reaction system by a conventionally known means, and can be further purified.
- Such purification methods include recrystallization, column chromatography, preparative thin-layer chromatography, Examples include an elution method and a reprecipitation method.
- Reaction Scheme 12 shows that a 5′- ⁇ 3 ⁇ 4-nucleoside derivative (lb) is bonded to the ⁇ -aminopropyl group of an amino acid in which both the amino group and the aminooxy group are protected via the 5′-amino group.
- a monomer compound 5 in which a nucleoside is bonded to the amino acid peptide main chain is synthesized (step 1), and the resulting monomer is used as a unit to repeatedly perform a selective deprotection-condensation cycle.
- the N-terminus of the monomer and The nucleoside derivative of the present invention is produced by continuously extending the C-terminal (steps 2 to 4).
- Step 1 is a reaction in which the ⁇ -carboxyl group of the amino acid or its derivative, which is a peptide main chain unit, is linked to the 5′-amino group of the nucleoside derivative as described above.
- An amino acid derivative in which a group (such as an ⁇ -carboxyl group) is protected and a 5′- ⁇ ⁇ 2 -nucleoside derivative (lb) produced according to the method of Step 1> in Reaction Scheme 11 described above are used. .
- amino protecting group for the amino acid used here general amino protecting groups used for peptide synthesis can be widely mentioned.
- amino protecting groups include, for example, an optionally substituted carbobenzoxy group, tributyloxycarbonyl group, 9-fluorenylmethoxycarbonyl group, phthalyl group, formyl group, acetyl group, trifluoroacetyl group Group, p-toluenesulfonyl group, triphenylmethyl group, cyclohexyloxycarbonyl group, 0-nitrophenylsulfenyl group, t-amyloxycarbonyl group, benzyl group, alkyl- or arylthio
- Examples include a carbonyl group, a 0-nitrophenoxyacetyl group, a chloroacetyl group, a benzenesulfonyl group, a dibenzylphosphoryl group, a trialkylsilyl group, an arylidene group
- a butoxyloxycarbonyl group and a 9-fluorenylmethoxycarbonyl group can be exemplified.
- the former is particularly useful in the liquid phase synthesis of the nucleoside derivative of the present invention because it is an amino protecting group that can be deprotected under acidic conditions, and the latter is particularly useful because it is an amino protecting group that can be deprotected under basic conditions. It is useful for the solid phase synthesis of the nucleoside derivative of the present invention.
- Examples of the carboxyl protecting group for amino acids generally include esters such as methyl ester, ethyl ester, tributyl ester, benzyl ester and P-nitrobenzyl ester, and ⁇ ′-substituted hydrazide. From the viewpoints of high yield and high selective deprotection, benzylylesterol ⁇ -two-opening benzyl ester, which can be removed by catalytic hydrogenation, is preferred.
- More preferred amino acids or derivatives thereof include an amino acid having an amino group protected with a t-butyloxycarbonyl group (Boc-) and a carboxyl group protected with a free or benzyl ester group (-OBzl) or a derivative thereof.
- amino acids in which the amino group is a 9-fluorenylmethoxycarbonyl group (Fmoc-) and amino acids in which the carboxy / group is free or protected by a benzyl ester group (-OBzl) or derivatives thereof can be exemplified.
- any of the N, ⁇ -C-protected amino acids into which any of the above protecting groups has been introduced can be produced according to a conventional method.
- the binding reaction between the N, ⁇ C-protected amino acid and the 5′- 2 -nucleoside derivative (lb) is performed by DCC (dicyclohexylcarbodiimide), WSC (7K-soluble dicyclohexylcarbodiimide), B0P (benzotriazole).
- DCC dicyclohexylcarbodiimide
- WSC 7K-soluble dicyclohexylcarbodiimide
- B0P benzotriazole
- condensing agents such as trioxytris (dimethylamino) phosphonium hexafluorophosphate and HOBt (dihydroxybenzotriazole), HONSu (N-hydroxysuccinimide), paranitrophenol, pentafluorophenol, pentachlorophenol, etc.
- the reaction can be carried out by an amide bond forming reaction using the system.
- the produced monomer (5) can be isolated and purified from the reaction solution according to a conventional method. Specifically, there can be mentioned a method of extracting the residue obtained by removing the solvent from the reaction solution with ethyl acetate, and then purifying the residue by column chromatography or the like.
- Steps 1 to 4 are steps for forming an oligomer by subjecting the monomer (5) obtained in the above ⁇ Step 1> to unity condensation and extension reaction. Specifically, (Selective deprotection-condensation cycle) by repeating the reaction cycle (selective deprotection-condensation cycle) consisting of the selective deprotection reaction of the carboxyl terminal and the amino terminal of the mer (steps 2 and 3) and the subsequent condensation reaction (step 4). (Deprotection-condensation / repetition cycle) This is a process for producing an oligomer (polymer).
- the selective deprotection-condensation cycle is performed as follows.
- the benzyl ester group which is the carboxyl protecting group of the N, C-protected monomer (5) formed in step 1> above, is eliminated by catalytic hydrogenation reaction, and the N-protection having a free carboxyl group is removed.
- the amino-protecting group and the carboxyl-protecting group are eliminated from the C-protected P RNA oligomer obtained above, and P RNA 2 (r PNA) having a free amino group and a carboxyl group is prepared by a conventional method.
- the method described in Example 3 can be specifically exemplified.
- the nucleoside derivative (1) of the present invention in which A in Formula (1) is a single pound can be produced.
- R 8 is an oxygen atom or a sulfur atom.
- any of the protecting groups described above in relation to PRNA 2 can be used as the amino-protecting group and the olepoxyl-protecting group of the amino acid.
- aminoethylene glycine (AEG) in which R 7 is a hydrogen atom, is used as the peptide main chain
- Boc-AE G-OBn produced using ethylenediamine as a starting material as a compound having N- and C-terminal protecting groups Is preferably used.
- steps A, B and C are performed as follows.
- step A the method of introducing a Boc group into 2-bromoethylamine (3a) can be performed according to a conventional method.
- 2-bromoethylamine (3a) dissolved in an appropriate solvent is specifically used.
- the reaction can be carried out by adding di-1-butyl dicarbonate ((Boc) 20 ) dropwise to the mixture.
- dioxane, THF, dimethylformamide, chloroform, methylene chloride and the like can be used as the solvent.
- the mixing ratio of di-tobutyl dicarbonate to 1 mol of 2-bromoethylamine (3a) is usually 1 to 2 mol, preferably about 1.2 mol.
- the dropping is preferably performed at a temperature in the range of 110 to 20 ° C.
- reaction product N-protected compound
- a conventional method Specifically, water is added to the residue obtained by removing the solvent from the reaction solution, and the resulting aqueous layer is extracted with a non-polar organic solvent such as black form.
- a non-polar organic solvent such as black form.
- a butoxycarponyl group is introduced into the amino group of the benzyl ester derivative of the amino acid by reacting the benzyl ester derivative of the amino acid with the N-protected compound obtained above (Boc-amino acid derivative-0Bn, N, C -Protected amino acid derivative) (3b).
- This reaction can be carried out in a solvent such as chloroform, methylene chloride, dioxane, dimethizoleformamide, dimethyl sulfoxide and the like.
- the mixing ratios of diisopropylethylamine and benzyl bromoacetate used in 1 mol of N-Boc_l, 2-aminoethane are about 0.5 to 2 mol and about 1 to 2 mol, respectively.
- the reaction is preferably performed in the range of 0-6. Usually, such a reaction is completed in 0.5 to 24 hours.
- the reaction product (N, C-protected amino acid derivative) (3b) obtained by the above reaction is separated from the reaction system and purified by a conventionally known means. Examples of such purification methods include recrystallization, column chromatography, preparative thin-layer chromatography, and solvent extraction.
- step 1 the 5'- 2- nucleoside derivative (lb) synthesized by the method of Reaction Scheme 11 (step 1) is reacted with the N, C-protected amino acid derivative (3b) obtained above.
- N, C-protected PRNA3 monomer (3c) can be produced.
- the 5′-N3 ⁇ 4-nucleoside derivative (lb) is previously reacted with ⁇ , ⁇ ′-carbonyldiimidazole (CDI), phosgene,, ⁇ ′ -thiocarponyldiimidazole (TCDI) or tiophosgene to obtain
- CDI ⁇ , ⁇ ′-carbonyldiimidazole
- TCDI phosgene
- TCDI ⁇ ′ -thiocarponyldiimidazole
- tiophosgene tiophosgene
- the mixing ratio of the above CDI and the like used for 1 mol of the 5′-NH 2 -nucleoside derivative (lb) is usually about 1 to 2 mol, preferably about 1 mol.
- This reaction is preferably performed at a low temperature in order to suppress a side reaction of the 5′-H 2 -nucleoside derivative (lb) with a 3 ′ friend and / or a 2 ′ hydroxyl group. It is preferably carried out in the range of -78 to -40.
- the reaction system is returned to room temperature, and the N, C-protected amino acid derivative (3b) is added.
- N, C-proportion of protected amino acid derivative (3b) is, 5 '- H 2 - nucleoside derivative (lb) normally 1-2 moles relative to 1 mole, preferably:! Is ⁇ 1 5 moles. .
- the reaction product (N, C-protected PRNA3 monomer (3c)) obtained by the above reaction is separated from the reaction system by a conventionally known means and purified.
- a purification method include a recrystallization method, column chromatography, preparative thin layer chromatography, a dissolution / dissolution method, and a precipitation method.
- the isolation and purification of the above product is preferably performed at room temperature or lower.
- the oligomerization of the resulting N, C-protected PRNA3 monomer (3c) can then be carried out in a conventional manner, for example, as described above for PRNA2, in the step of elimination of the lipoxyl protecting group.
- a so-called selective deprotection comprising a step 3 for elimination of an amino-protecting group, and a step 4 for condensing the C-protected product and the N-protected product by an amide bond forming reaction. Examples include a method of repeatedly performing a condensation cycle, a solid phase synthesis method, a sequential condensation method, and a fragment condensation method.
- nucleoside derivatives in which A is a carbonyl group include serine, threonine, aspartic acid, glutamic acid, lysine, arginine, cystine and orditin, ⁇ -hydroxylysine, ⁇ -aminoethylglycine, ⁇ -aminoethylserine, ⁇ -aminoethyllysine, ⁇ -aminoethylorutin, ⁇ -aminoethylaspartic acid, ⁇ -aminoethylglutamic acid, or N, N '
- the nucleoside derivative in which ⁇ is a thiocarbonyl group can be prepared by reacting with the above amino acid derivative or an oligomer or polymer thereof by reacting with thiopyrrondiimidazole (CDI) or phosgene.
- Nildimidazole or thiophosge It can be produced by reacting with The nucleoside derivatives of the present invention, Te nucleoside derivatives smell of the general formula (1), - ( ⁇ - ⁇ '),) ⁇ -.
- eta 1 shows Amino acids, amino acid derivatives or their amino-terminal amino groups are protected with a tert-butoxycarbonyl group (Boc-group) or a 9-fluorenylcarbonyl group (Fmoc_ group), and the C-terminal carboxyl group
- the groups include free or mono-nucleoside derivatives (PRNA monomers) protected with benzyl esters.
- the 9-fluorenylcarbonyl group (Fmoc -group) is an amino protecting group that can be reversibly deprotected under basic conditions. Therefore, the mononucleoside derivative in which the N-terminus is protected by a Tmoc- group is useful as a raw material for solid-phase synthesis of an oligo or polynucleoside derivative as an Fmoc-PRNA monomer (Fmoc-mononucleoside derivative).
- the Fmoc-mononucleoside derivative (Fmoc-PRNA monomer) can be prepared by compound 5 (N, C-protected PRNA2 monomer) prepared according to the above-mentioned reaction formula 12 or compound 3 c (N , C-protected PR A3 monomer) as raw material, first deprotection of N-terminal Boc-group by TFA, then introduction of Fmoc- group using Fmoc-Osu (N- (9-fluorenylcarbonyloxy) succinimide) By doing.
- Mononucleoside derivative in which terminal hydroxyl group is protected with benzyl ester Can be prepared as Further, by removing the protecting group at the C-terminal according to a conventional method such as catalytic reduction, a mononucleoside derivative (PRNA monomer) 9 having a free hydroxyl group can be prepared.
- the solvent used for the catalytic reduction, especially DMF, is preferably purified and used so as not to contain free amine.
- the present invention can provide a solid phase synthesis method of an oligo or polynucleoside derivative using the Fmoc-mononucleoside derivative, particularly the Fmoc-PRNA monomer, as a raw material by providing the monomer.
- the oligo or polynucleoside derivative of the present invention can be automatically synthesized using an apparatus.
- the solid-phase synthesis of the oligo- or polynucleoside derivative of the present invention can be carried out by using the above-mentioned Fmoc-mononucleoside derivative (Fmoc-PRNA monomer) as a raw material of a monomer using a conventionally known peptide solid-phase synthesis method (for example, , GR Marchall, RB Merrifield, "Biochemical Aspects of Reactions on Solid Supports, Ed. By GR Stark, p. Ill-169, Academic Press, NY (1971), etc.)
- the solid phase used for the synthesis may be a solid phase carrier widely used for the conventionally known peptide solid phase synthesis method, and the coupling reaction may be carried out.
- Fmoc-PRNA monomer Fmoc-mononucleoside derivative
- Kaiser test using a ninhydrin reagent
- step 1 Introducing the monomer) into the solid support (step 1), removing the amino protecting group of the Fmoc-nucleoside derivative (Fmoc-PRNA) (step 2), and adding the N-terminal of the N-deprotected nucleoside derivative
- step 3 The step of condensing the Fmoc-mononucleoside derivative (Fmoc-PRNA monomer) (step 3), the coupling reaction of step 3 and the elimination step of step 2 are repeated to successively extend the mononucleoside derivative (PRNA monomer) Step (Step 4), a step of cutting out the obtained nucleoside derivative polymer from the solid support (Step 5) can be produced.
- the condensation reaction confirmatory test such as Kaiser one test to confirm the progress of the reaction.
- the reaction confirmation test by alternating the condensation reaction, reliably Fmoc-PRNA monomer can be condensed and extended.
- the nucleoside derivative (1) of the present invention can be used as an antisense molecule in an antisense method.
- the nucleoside derivative of the present invention can be used as it is, but it can also be used as a so-called chimeric molecule in a form incorporated in a part of a base sequence such as a DNA sequence, an RNA sequence, or a DNA / RNA derivative.
- derivatives of DNA and RNA include those having the same physiological function as nucleic acids such as DNA and RNA, and nucleic acid derivatives that are presently or in the future, such as nucleic acid derivatives conventionally known as antisense molecules such as PNA.
- the body is included.
- a derivative of DNA or RNA those represented by the following formula can be exemplified.
- R 9 is an oxygen atom or a sulfur atom
- R 1Q is O-, S-, NH 2 , NHR 11 , NRUR 12 , or R 11 .
- R 11 and R 12 are the same or different and are CH 3 , (CH 2 ) nCH 3 , (CH 2 ) nNHZ, (CH 2 ) nNZZ, or (CH 2 ) nNH 2 [Z or Z ′ Are the same or different and are lower alkyl groups having 1 to 4 carbon atoms such as methyl group, ethyl group, propyl group, n-propyl group, tributyl group, i-butyl group and n-butyl group; Is an integer of 0 to 10.]
- the nucleoside derivative of the present invention can be bound to DNA, RNA or a derivative thereof directly or via a spacer.
- the mode of such a bond is not particularly limited, in the case of a direct bond, the 3 ′ or 5 ′ end of the nucleoside derivative has a phosphodiester bond, a methylphosphonate bond at the 5 ′ end or 3 ′ end of the DNA or a derivative thereof, Methylphosphonothioate bond, phosphorothioate
- the binding method include a bond bond, an amide bond, a sulfoamide bond, an ethylene glycol bond, and a thiomalimarin bond.
- the nucleoside derivative of the present invention binds to DNA, RNA or a derivative thereof via a spacer
- the 5,1-amino group of DNA, RNA or a derivative thereof and the carboxyl group of the nucleoside derivative may be used.
- nucleoside derivative can be bound to DNA, RNA or a derivative thereof according to a conventional method.
- nucleoside derivative of the present invention and the above-mentioned chimeric molecule containing the derivative may be prepared as a pharmaceutical preparation by mixing pharmaceutically acceptable conventional additives such as buffers, stabilizers, and diluents, and a carrier.
- pharmaceutically acceptable conventional additives such as buffers, stabilizers, and diluents, and a carrier.
- Such preparations can be used for various mammals including humans, and various administration forms can be adopted according to the purpose. Examples of such a form include parenteral preparations such as injections, suppositories, external preparations, eye drops, nasal drops, catheter administration, and the like, which can be produced by methods well known in the art.
- nucleoside derivatives and the chimeric molecules of the present invention according 9 which can be applied to use to the plant cells as pesticides and plant modifier is also not particularly limited, tablets, capsules, prepared in the form of a solution, such as You can also.
- peracyl pyrimidine nucleobase
- inosine purine nucleobase
- dartamic acid is mainly used as the amino acid or its derivative ( ⁇ , ⁇ ,).
- other nucleobases and amino acids or derivatives thereof can be used as well.
- N 4 -benzoylcytidine (13.3 g, 96%).
- the N 4 —benzoylcytidine (13.0 g, 37.4 mmol), trifenylphosphine (28.0 g, 107 marl ol) and lithium azide (13.0 g, 266 mmol) were suspended in dry DMF, and the suspension was added to the suspension.
- carbon tetrabromide (35.5 g, 107 t ol).
- ethyl acetate (1500 ml) was added, and the mixture was washed with water and saturated saline (1000 ml each).
- PRNA 2 Peptide liponucleic acid having an oligo ( ⁇ -L-glutamic acid) skeleton was produced according to the following reaction formula.
- Glutamic acid with amino-terminal protected by t-butoxycarbonyl group and carbonyl group by benzyl ester group N-1-butoxycarbonyl-L-glutamic acid a-benzylester (Boc-isoGln-OBzI) (2.52 g, 7.47 mmol) ), HOBT (l. Olg, 7.47 band01) and OP reagent (benzotriazole-trioxytris (dimethylamino) phosphorum hexafluorophosphate) (3.30 g, 7.47% 01) Diisopropylethylamine (1.30 ml, 7, 47 t) was added to the solution (100 ml).
- Boc-isoGln (5'U) -OH (compound 6) (1.25 g, 2.65 mmol), HOBt (0.358 g, 2.65 thigh 01) obtained in (2) above, and 80?
- Reagent 1.173, 2.65 t ) was dissolved in DMF solution (50 ml), and diisopropylethylamine (0.97 ml, 5.57 mol) was added to the mixture.
- the TFA'isoGln (5'U) -OBzl (compound 7) (1.68 g, 2.92 tmol) obtained in (3) above was added, and the reaction solution was added. Stirred at room temperature for 2 hours.
- Boc- (isoGln (5'U)) 4 -OBzl (0.600 g, 0.369 ol) obtained in (7) above was added to the methanol-DMF solution (1: 1 v / v, 30 ml) of (11). Palladium on carbon (10, about 0.1 lg) was added. After continuously stirring under a hydrogen atmosphere (lbar) for 4 hours, the reaction solution was filtered and the filtrate was distilled off under reduced pressure to obtain a powdered tetramer Boc- (isoGln (5'U)) 4 -0H (Compound 12) was obtained (0.550 g, yield 97).
- the Boc- (isoGln (5′U)) 4 -OBzl (compound 11) (0.600 g, 0.369 t ol) obtained in the above (7) was dissolved in TFA (5 ml), and the solution was set at 0 for 30 minutes. I left it. Then, TFA was distilled off under reduced pressure, and 100 ml of ether was added to obtain TFAisoGln (5'U) 4 -OBzl (compound 13) in powder form (0.593 g, yield 98%).
- PRNA 2 having a free N-terminus was prepared according to the following reaction formula.
- Boc- (isoGln (5'U) 8 -Lys (CIZ) -Bzl (compound 16) obtained in (1) above (0.300 g, 0.0 90 cafe ol) was dissolved in TFA (10 ml) and the solution was stored under a -nitrogen atmosphere at 110.
- m-cresol (0.97 ml, 9.27 orchid) and trimethylsilal triflate (3.00 ml, 16.6 benzyl) were added sequentially, and the mixture was stirred at 0 for 1 hour. did.
- Ether 200 ml was added and the precipitate was filtered. The precipitate was dissolved in a 5% aqueous ammonia solution.
- Boc-AEG-OBn was produced according to the following reaction formula.
- N-Boc-1,2-aminoethane (4.64 g, 29.0 t ol) and disopropylethylamine (4.50 g, 34.8 dandelion ol) were dissolved in black mouth form (40 ml).
- Boc-AEG (5'U) -OBn was prepared according to the following reaction formula c
- Boc- AEG (5 'U)-OBn 5′-Amino-5′-doxyduridine (5, -H 2 -Urd) (1.80 g, 7.40 mmol) prepared in Reference Example 1 was dissolved in dry DMF (50 ml), and -5 (- In TC, a solution of CDI (1.14 g, 7.04 brainol) in DMF (40 ml) was added dropwise over 1 hour, and the reaction system was stirred at ⁇ 50 for 30 minutes, and then gradually heated to room temperature.
- Boc-AEG-0Bn (1.72 g, 7.40 mmol) was added, and the mixture was stirred at room temperature for 2 days.After completion of the reaction, DMF was distilled off under reduced pressure at room temperature, and the residue was subjected to column chromatography. (Silica gel; chloroform-methanol (20: 1 v / v)) to obtain Boc-AEG (5′U) -0Bn (2.64 g, 4.58 g, yield 65%). White solid.
- Example 5 Using Boc-AEG (5'U) -0H and TFAAEG (5'U) -OBn prepared above, dimer Boc- (AEG (5'U)) according to the method of Example 2 (4). 2.) Prepare 2- OBn. Furthermore, an oligomer can be prepared according to the method of Example 2 (5) to (: 11).
- Example 5 Using Boc-AEG (5'U) -0H and TFAAEG (5'U) -OBn prepared above, dimer Boc- (AEG (5'U)) according to the method of Example 2 (4). 2.) Prepare 2- OBn. Furthermore, an oligomer can be prepared according to the method of Example 2 (5) to (: 11). Example 5
- Example 2 obtained in (5) Boc- (isoGln (5'U )) 4 - 0H ( Compound 9) 343mg (0.37imol), distilled DMF and HOB t 56mg (leq) and BOP reagent 184 mg (leq) The mixture was dissolved at 0 ° C and stirred for about 1 hour until the temperature returned to room temperature. To this solution, 131 mg (2 eq) of diisopropylethylamine (DIEA) was added, and then TFAisoGln (5′U) -OBzl (compound 7) obtained in Example 2 (3) (251 mgaeq) was added. And stirred at room temperature for 2 hours. After the reaction, the solvent was concentrated under reduced pressure and reprecipitated from ethanol to obtain a trimer Boc- (isoGln (5'U)) 3 -OBzl. Yield 200mg, Yield 37.9%
- Boc- (isoGln (5'U)) 3 -OBzl (200nig) obtained above was dissolved in methanol and added with palladium-supported carbon (10%, about 40 mg). By about 2 hours under a hydrogen atmosphere, Boc-by reprecipitation by E one ether (isoGln (5'U)) to obtain a 3 -0H. Yield 190 mg, yield 9
- Boc-isoGln (5'I) -OBzl (1.09 g, 1.86 t ol) obtained in (1) above in methanol, add about 40 mg of carbon supported on palladium, and react for about 2 hours under hydrogen atmosphere.
- Boc-isoGln (5'I) -0H was obtained. Yield 900mg, Yield 97.5
- Boc-isoGln (5'I) -0H (182 mg, 0.37 t ol), HOB t (50 rag, 1 eq) and B ⁇ P reagent (162 mg, 1 eq) obtained in the above (2) were added to distilled DMF. And stirred for about 1 hour until the temperature returned to room temperature. To this solution was added 115 mg (2 eq) of diisopropylethylamine (DIEA), and 220 mg (leq) of TFA'isoGln (5'I) -OBzl prepared in (3) was added. Stirred for hours.
- DIEA diisopropylethylamine
- Example 2 Boc-isoGln (5'U) -0H (compound 6) prepared in (2) 945 mg (2.Ommol), HOB t 270 mg (leq) and BOP reagent 890 mg (leq) were dissolved in distilled DMF at 0. Then, the mixture was stirred for about 1 hour until the temperature returned to room temperature. To this solution, 0.74 mg (2 eq) of diisopropylethylamine (DI EA) was added, and then 1.32 g (l.l) of the TFAisoGln (5'I) -0 Bzl prepared in Example 6 (3) above was added. leq), and the mixture was stirred at room temperature for about 2 hours.
- DI EA diisopropylethylamine
- Boc-isoGln (5'U) -isoGln (5'I) -OBzl (527 mg, 0.56 fraction 1) prepared in (1) above was dissolved in methanol, and the palladium-supported carbon (10%, about 40fflg) was dissolved. Was added. The reaction was carried out for about 2 hours under a hydrogen atmosphere to obtain Boc_isoGln (5′U) -isoGln (5′I) -0H (yield 466 mg, 98%).
- Boc-isoG1n (5'U) -isoGln (5'I) -OBz1 prepared in the above (1) was dissolved in TFA and reacted at 0 for 2 hours. Then, TFA was distilled off under reduced pressure, and ether was added to obtain TFA.isoGln (5'U) -isoGln (5'I) -0Bzl. Yield 798 mg, 98%.
- Boc-isoGln ((5′U) -isoGln (5, I)) 2 -0H 65 mg (4.1 Xl (T3 ⁇ 4ol), HOBt 5.5 mg (leq) and BOP reagent 18.2 mg (leq) prepared in (5) above) was dissolved in distilled DMF with and stirred for about 1 hour until the temperature returned to room temperature.12.9 mg (2 eQ) of DIEA was added to this solution, and then the TFA ′ isoGln ((5 ′) prepared in the above (6) was added.
- ⁇ -NR (270MHz; DMSO): (51.35 (s, 9H), 1.79 (m, 4H), 2.15 (m, 2H), 2.33 (t, 2H), 3.76-4.13 (m, 7H), 4.27 ( q, IH), 4.55 (q, IH), 5.04 (s, 2H), 5.17 (d, IH), 5.39 (d, lH), 5.51 (d, lH), 5.64 (d, lH), 5.73 ( d, IH), 5.83 (d, IH), 6.87 (d, IH), 7.34 (m, 5H), 7.64 (d, lH), 7.91-8.05 (m, 2), 8.11 (s, lH), 8.31 (s, IH);
- Boc-isoGln (5'I) -isoGln (5'U) -0Bzl (527 mg, 0.56 ol) prepared above was dissolved in methanol, and palladium on carbon (10%, about 40fflg) was added. The reaction was performed under a hydrogen atmosphere for about 2 hours to obtain Boc-isoGln (5'I) -isoGln (5'U) -0H (yield 410 mg, 91%).
- Example 2 2.196 g (3.81 mmol) of TFA * isoGln (5'U) -OBzl (compound 7) prepared in (3) and Fmoc-Osu (N- (9-fluorenylcarponyloxy) succinimide) 1.537 g (l. 2 eq) was dissolved in distilled DMF at 0 ° C and stirred. 1.99 g (2 eq) of DIEA was added to this solution, followed by stirring at room temperature for 30 minutes. The solution was concentrated under reduced pressure, and methanol was added to obtain Fmoc-isoGln (5'U) -OBzl by crystallizing. Yield 2.156g, Yield 82.8%
- PRNA oligomers were produced according to the scheme described in FIG.
- a solid-phase carrier resin NovaSyn (registered trademark) TGR-Resin (manufactured by Pharmacia) having a polyethylene dalicol chain as a spacer was used.
- the solid phase carrier in which the amino group is protected by the oc-group is well swollen with N-methylpiperidone (NMP), and then reacted with 20% piperidine (PPD) ZNMP for 15 minutes.
- NMP N-methylpiperidone
- PPD piperidine
- the Fmoc protecting group was removed from the solid support resin.
- the mixture was vortexed every 5 minutes, and washed 5 times with NMP after completion of the reaction.
- the PA extension reaction was carried out by successively condensing Fmoc-PRNA monomers having an Fmoc protecting group at the N-terminus and free at the C-terminus by repeating the following reaction.
- Fmoc-PRA monomer (3 eq to resin) and 2- (1H-benzotriazole-toluyl) -1,1,3,3-tetramethylperonium hexafluorophosphate ) (HBTU) (3 eq) and 1-hydroxybenzotriazole (HOBt) (3 eq) were dissolved in NMP, introduced into a column packed with the above resin, and diisopropylethylamine (DIEA) (6 eq) was added. The reaction was performed for 0 minutes. The mixture was ported every 5 minutes, and washed 5 times with NMP after completion of the reaction.
- DIEA diisopropylethylamine
- the N-terminus of the PRNA oligomer was deprotected by treating with 20% PPDZNMP and washed five times with NMP. The resin was further washed five times with a black hole form and the resin was dried under vacuum. The synthetic PRNA oligomer was then excised from the resin with TFA containing 5% water as a scavenger. TFA was distilled off with an evaporator, and the TFA solution was passed through the column and added to cold ether to obtain a white solid precipitate. It was then centrifuged. The supernatant was removed by decantation, and the residue was dried under vacuum to obtain a crude product of P-leg oligomer.
- the crude product was subjected to analytical HPLC under the following conditions to confirm that it was a single peak, and the molecular weight was identified by MALDI-TOF. Further, the target fraction was fractionated through a preparative column, and the obtained fraction solution was freeze-dried to obtain a white solid.
- Solution A Adjust the composition of Solution B from 100: 0 to 0: 100 for 30 minutes
- FIG. 2 shows the results of HPLC analysis.
- a condensation extension reaction is performed using the above Fmoc-isoGIn (5'U) -0H and iFmoc-isoGln (5'I) -0H as the aforementioned Fmoc-PRNA monomer, and the final condensation reaction was performed using Fmoc-Lys (OBzl) -0H to synthesize the following two types of octamer PRNA.
- a chimeric nucleic acid (PRNA (Urd) -DNA (Thd) dimer) of PRNA having peracyl as a base and DNA having thymine as a base was synthesized according to the following scheme.
- Example 2 N 4 - 1-Butokishikarupo two Lou N s - (5 - Dokishi - 5, - Urijiru) - alpha of L- Isoguruta Minbe Njiruesuterire (Boc-isoGln (OBzl)) - a carboxyl group,
- Example 2 5′-H 2 -Urd (Reference Example 1) was introduced using the B0P reagent and HOBt according to the method described in Example 2, and then the a-carpoxyl group was removed by catalytic reduction according to Example 2 (2).
- Boc-isoGln (5'U) -0H was synthesized (88% yield).
- the 5′-hydroxyl group of thymidine is protected with a 4,4′-dimethoxytrityl chloride (DMTr-C1) group according to the method described in (1) to generate 5, -DMTr-Thd.
- DMTr-C1 4,4′-dimethoxytrityl chloride
- CEDIPA cyanoethyl ⁇ , ⁇ '-bis (diisopropyl) chlorophosphodiamidite
- the 3'-amidite derivative of 5'-aminothymidine (5'-DMTr-NH-3'-CEDIPA-Thd) is condensed by activating with DIPA and tetrazole and then deprotected with TCA again.
- a thymidine tetramer having an amino group at the 5 'end was synthesized.
- the nucleoside derivative of the present invention is not easily degraded not only for exonuclease but also for endonuclease, and can exist in a living body for a long time after administration to the living body. Further, the nucleoside derivative of the present invention has excellent affinity for nucleic acids (RNA, DNA). Therefore, the nucleoside derivative of the present invention can be prepared as it is as an antisense molecule, or as an antisense molecule by introducing it into another molecule such as DNA, RNA or a derivative thereof. Furthermore, the nucleotide derivatives of the present invention are useful as antisense molecules in this sense because their in vivo degradation products are nucleotide-amino acid derivatives and have no or very low biotoxicity.
- antisense molecules are used in antisense methods to control gene expression.
- the nucleoside derivative of the present invention can inhibit the function of the target gene by using it as an antisense molecule, and is effective in treating genetic diseases such as cancer and genetic diseases.
- the nucleotide derivative of the present invention has a base moiety that is syn- It has the property that it can be switched to the orientation and from the syn orientation to the anti orientation. Therefore, by controlling such conditions, it is possible to control the ability of the gene to bind to the nucleotide sequence, and a new antisense molecule capable of reversibly controlling on-off of gene function expression in the antisense method. It is expected as.
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01938631A EP1295891A4 (en) | 2000-06-13 | 2001-06-13 | nucleoside |
US10/311,048 US6872809B2 (en) | 2000-06-13 | 2001-06-13 | Nucleoside derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000177428 | 2000-06-13 | ||
JP2000-177428 | 2000-06-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001096355A1 true WO2001096355A1 (fr) | 2001-12-20 |
Family
ID=18679026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/005011 WO2001096355A1 (fr) | 2000-06-13 | 2001-06-13 | Derives de nucleosides |
Country Status (3)
Country | Link |
---|---|
US (1) | US6872809B2 (ja) |
EP (1) | EP1295891A4 (ja) |
WO (1) | WO2001096355A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4005634A4 (en) * | 2019-07-24 | 2023-11-08 | Tohoku University | CHIMERIC MOLECULE, PHARMACEUTICAL COMPOSITION, METHOD FOR CLEAVING TARGET NUCLEIC ACID, AND KIT FOR CLEAVING OR DIAGNOSING TARGET NUCLEIC ACID |
-
2001
- 2001-06-13 US US10/311,048 patent/US6872809B2/en not_active Expired - Fee Related
- 2001-06-13 WO PCT/JP2001/005011 patent/WO2001096355A1/ja active Application Filing
- 2001-06-13 EP EP01938631A patent/EP1295891A4/en not_active Withdrawn
Non-Patent Citations (3)
Title |
---|
See also references of EP1295891A4 * |
TAKEHIKO WADA ET AL.: "Peptide ribonucleic acids (PRNA) 2.A novel strategy for active control of DNA recognition through borate ester formation", J. AM. CHEM. SOC., vol. 122, no. 2, July 2000 (2000-07-01), pages 6900 - 6910, XP002944753 * |
TAKEHIKO WADA ET AL.: "Synthesis and properties of oligo-omega-amino acids derivatives containing nucleosides", NUCLEIC ACIDS SYMPOSIUM SERIES, no. 34, 1995, pages 189 - 190, XP002944754 * |
Also Published As
Publication number | Publication date |
---|---|
EP1295891A4 (en) | 2004-05-26 |
US20030208050A1 (en) | 2003-11-06 |
EP1295891A1 (en) | 2003-03-26 |
US6872809B2 (en) | 2005-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU747998B2 (en) | Complex formation between dsDNA and oligomer of heterocycles | |
JP2758988B2 (ja) | ペプチド核酸 | |
JP3210672B2 (ja) | 新規ペプチド核酸 | |
JP3231045B2 (ja) | 固体支持体上でのポリピロール及びポリイミダゾールカルボキサミドの合成方法 | |
JP2021500311A (ja) | オリゴヌクレオチド調製のための技術 | |
WO1998013381A1 (fr) | Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant | |
AU698210B2 (en) | Polyamide-oligonucleotide derivatives, their preparation and use | |
CA2498772A1 (en) | Modified pna molecules | |
TWI298328B (en) | Polyamide nucleic acid derivatives, and agents and process for preparing them | |
US5849893A (en) | Nucleic acid-binding oligomers possessing C-branching for therapy and diagnostics | |
CA2288806A1 (en) | Complex formation between dsdna and oligomer of heterocycles | |
JP2001500387A (ja) | ペプチド核酸のモノマー及びオリゴマー | |
CN110974975B (zh) | 一种快速释放的抗体药物偶联物 | |
JP2022552757A (ja) | カンプトテシン類医薬品及びその抗体複合体 | |
CN107074911A (zh) | 肽核酸单体和低聚体 | |
KR20190055256A (ko) | 히프 1-알파 안티센스 올리고뉴클레오티드 | |
AU2001246536B2 (en) | Polyamide nucleic acid derivatives, agents and methods for producing the same | |
WO2001096355A1 (fr) | Derives de nucleosides | |
JPH11515032A (ja) | ドラスタチン15のペプチド誘導体およびその使用 | |
CA2155496A1 (en) | Nucleic acid-binding oligomers for therapy and diagnosis | |
US7038037B2 (en) | Method for sequential support-bound synthesis of conjugated oligomeric compounds | |
Zhu et al. | Preparation of vitamin B6-conjugated peptides at the amino terminus and of vitamin B6-peptide-oligonucleotide conjugates | |
JP2023508440A (ja) | 溶液工程でのpnaオリゴマーの製造方法 | |
de Koning et al. | Synthesis of a PNA-peptide conjugate by chemical ligation | |
WO2001096356A1 (fr) | Molecules antisens et procede de commande de l'expression d'une fonction genique les utilisant |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10311048 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 510496 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001938631 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001938631 Country of ref document: EP |